Obesity
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global obesity drug development, market trends, and regulatory landscapes. Drive your pharma strategy with NovaPharmaNews intelligence.
Showing 1–12 of 34 articles
Quick answer
NovaPharmaNews Obesity hub for FDA covers 34 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Weight Loss Medications in 2026: GLP-1 Market Shift
Chile warning labels on food: new evidence on efficacy and obesity risk
Obesity rates in America by year: what the data shows
GLP-1 usage statistics show broad uptake and mixed clinical signals
MariTide Phase 2 obesity data show up to 20% weight loss at one year
Danuglipron Phase 3 Watch After Pfizer’s Phase 2b Obesity Win
MariTide Phase 2: Amgen reports up to 20% weight loss at one year
Eli Lilly raises 2026 revenue guidance on Mounjaro demand
Pfizer's Danuglipron Hits Phase 2b Obesity Endpoint
Triple Hormone-Receptor Agonist Retatrutide for Obesity: Phase 3 Results and Market Impact
Pfizer's Berobenatide Obesity Drug: VESPER-3 Data and Competitive Outlook
Eli Lilly Retatrutide Phase 3: Safety Data and Competitive Implications
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.